You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020221015
Dec 20202806
Jan 202178013
Feb 2021177017
Mar 2021274033
Apr 2021324034
May 2021107025
Jun 20210022
Jul 20210025
Aug 20210021
Sep 20211014
Oct 202183029
Nov 2021132043
Dec 202184014
Jan 202211807
Feb 20228405
Mar 202274011
Apr 20228207
May 20228409
Jun 202212009
Jul 2022108010
Aug 202284011
Sep 20228208
Oct 20225804
Nov 2022104010
Dec 20223404
Jan 202398014
Feb 202313406
Mar 202372010
Apr 20235608
May 20237806
Jun 202396013
Jul 20233406
Aug 202360012
Sep 20234607
Oct 2023106012
Nov 20236808
Dec 20233801
Jan 20242800
Feb 20244202
Mar 20244203
Apr 20249402
May 20243802
Jun 20244106
Jul 20244102
Aug 20244209
Sep 20243908
Oct 20243007
Nov 20244003
Dec 20242409
Jan 202552025
Feb 2025202
Mar 2025007
Apr 2025005
May 2025005
Jun 2025102
Total39830608